[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China] [0.03%]
伊沙佐米/来那度胺/地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性特征：中国的多中心真实世界研究
Y Yang,Z J Xia,W H Zhang et al.
Y Yang et al.
Objective: To evaluate the efficacy and safety profile of ixazomib/lenalidomide/dexamethasone (IRd) in Chinese patients with relapsed/refractory multiple myeloma (MM) . Methods: This study comprising 14 medical centers in China included pat...
[Chinese guidelines for the diagnosis and treatment of relapsed/refractory acute myelogenous leukemia (2021)] [0.03%]
中国复发/难治性急性髓系白血病诊断治疗指南(2021年版)
Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association
Leukemia & Lymphoma Group
[Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)] [0.03%]
中国成人急性髓系白血病(非APL)诊断与治疗指南(2021版)
Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association
Leukemia & Lymphoma Group
[IgG lymphoplasmacytic lymphoma complicated with secondary fanconi syndrome: a case report] [0.03%]
[igg淋巴浆细胞型淋巴瘤合并继发性范可尼综合征1例]
L Wang,X Y Wang,H F Ding
L Wang
[New mutation of congenital sideroblastic anemia: a case report and literature review] [0.03%]
先天性铁粒幼细胞贫血新突变一例及文献复习
X Han,Q Wen,X Liu et al.
X Han et al.
[The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma] [0.03%]
PD-1、TIM-3、LAG-3和BTLA在鼻自然杀伤/T细胞淋巴瘤中的表达及其预后价值分析
L Nie,X Y Liu,R J Ma et al.
L Nie et al.
[Prognostic analysis of patients with mutations in the JAK/STAT signaling pathway in adult acute lymphoblastic leukemia] [0.03%]
成人急性淋巴细胞白血病JAK/STAT信号通路突变患者的预后分析
W J Fan,T T Xu,J J Guo et al.
W J Fan et al.
[Outcome of haploidentical hematopoietic stem cell transplantation for aggressive natural killer cell leukemia] [0.03%]
单倍体相合造血干细胞移植治疗急进性自然杀伤细胞白血病的疗效分析
J Xia,S N Chen,Z M Jin et al.
J Xia et al.